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Abstract
Background A retrospective analysis was carried out from patients and controls during the past 5 years from a series of
studies investigating endothelial microparticles (MP).
Methods In total, 319 samples from 207 individuals were included in this analysis, from patients with type 2 diabetes (T2D,
n= 105), women with polycystic ovary syndrome (PCOS, n= 145) and healthy volunteers (n= 69). All data were gen-
erated via the same ﬂow cytometry protocol with the same antibody clones. Endothelial markers CD105 (Endoglin) and
CD106 (Vascular cell adhesion molecule-1) were used to enumerate MP in venous blood.
Results The ratio of CD105MP:CD106MP was signiﬁcantly different between groups (F= 63.43, p < 0.0001). Women with
PCOS were found to have a median CD105MP:CD106MP ratio of 0.40 (IQR 0.24–0.57), suggesting approximately two
CD106MP were found per CD105MP. The T2D group showed a median ratio of 2.32 (1.51–3.69) whereas in healthy
volunteers the ratio was 2.21 (1.63–3.55). Serum intercellular adhesion molecule-1 was also shown to be signiﬁcantly
increased in PCOS when compared with control or T2D groups (F= 14.5, p < 0.001).
Conclusion These data suggest that women with PCOS have an altered endothelial MP release in favour of CD106. Thus a
potential activated endothelial state exists in women with PCOS with a shift towards a predominantly CD106MP proﬁle.
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Introduction
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder amongst women of reproductive age
that commonly presents with menstrual irregularities,
ovulatory dysfunction and clinical and/or biochemical
hyperandrogenism [1, 2]. PCOS shares several risk factors
with metabolic syndrome such as insulin resistance,
impaired glucose tolerance, obesity, hypertension and
dyslipidaemia; thus these patients are at high risk of
developing diabetes mellitus and cardiovascular disease
[3]. In addition, PCOS is associated with endothelial dys-
function that is one of the earliest and most prominent signs
and a prognostic marker of future atheromatous cardio-
vascular disease [4]. Dysfunctional endothelium results in
abnormal activation and adhesion of platelets and leuco-
cytes, as well as the release of cytokines, thus increasing
permeability of the vessel wall to oxidised lipoproteins and
inﬂammatory mediators, resulting in arterial wall structural
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damage and atherosclerotic plaque formation [5, 6]. Mul-
tiple metabolic cardiovascular risk factors, common in
PCOS, accelerate the process of endothelial dysfunction
portending an increased risk of cardiovascular events in
these patients [7].
Cell derived microparticles (MP) are a heterogeneous
population of extracellular vesicles (0.1–1 μm) that are
released from the cell membrane during cell activation and
apoptosis and contribute to the induction of endothelial cell
modiﬁcations, differentiation, inﬂammation and angiogen-
esis [8]. MPs are also vital messengers in inter-cellular
communications [8]. They have been suggested to play a
signiﬁcant role in endothelial dysfunction, cellular inﬂam-
mation, coagulation and angiogenesis, and thus predispose
to cardiovascular diseases by perturbing vascular homo-
eostasis. Recent trials have revealed that PCOS patients
have higher levels of endothelial microparticles (EMP) [8].
EMP levels are also increased in a variety of cardiovascular
and atherothrombotic diseases such as diabetes, obesity,
end-stage renal disease, acute coronary syndromes, cancers,
inﬂammatory disorders and autoimmune diseases [9]. In
both acute coronary syndrome and diabetic patients, EMP
correlate positively with the extent and severity of stenosis
and represent a more robust predictor of the occurrence of
cardiovascular events in diabetic patients compared with
traditional markers of endothelial activation [10].
The physiological relevance of MP is becoming clearer;
however, there are variations across laboratories in terms of
sample handling and analysis that have been addressed to
some extent by protocol standardisation [11] although a
large variation in reported quantiﬁed values exists. Most
studies, if not all, report on either a single speciﬁc marker or
multiple (usually dual) labelling to allow differentiation
between cells of origin, and often include Annexin V as an
apoptotic marker.
The aim of the study was to investigate EMP populations
as ratios of constitutively expressed (CD105; Endoglin)
versus activation markers (CD106; Vascular cell adhesion
molecule-1). This new method of analysis removes the
variations mentioned above by standardising measurements.
Data included in the study was produced from a range of
previous studies on women with PCOS, patients with type 2
Diabetes (T2D) and healthy controls.
Methods
Patient cohorts
Patients were recruited into studies between 2014 and 2019,
where EMP were determined prior to any interventions.
Four studies analysed here consisted of women with PCOS
(PCOS groups 1–4). Two further studies recruited patients
with T2D (T2D groups 1 and 2) and control groups (control
groups 1 and 2). Informed consent was given in accordance
with favourable ethical opinion for each separate study
(REC references; 14/YH/1125, 17/YH/0118, 16/NW/0518,
16/YH/0183). All volunteers were treated in accordance of
the principles of the Declaration of Helsinki.
EMP analysis
Venous blood samples were drawn from the antecubital
vein into citrated sample tubes (Vacutainer, Greiner, UK)
and analysed within 2 h from the time of collection. Pla-
telet free plasma was prepared via a double centrifugation
step, ﬁrst the blood sample tubes were centrifuged at
400 × g for 10 min. Platelet rich plasma was removed from
the tube and centrifuged again at 10,000 × g for 10 min to
remove platelets. The platelet free plasma (25 μL) was
incubated with 5 μL of either an anti-human CD105:FITC
(clone SN6, Bio-Rad, UK) or an anti-human CD106:FITC
(clone 1.G11B1, Bio-Rad, UK) for 30 min in the dark at
room temperature. Counting beads (25 μL, Accucheck
counting beads, Invitrogen, UK) and 0.2 μm ﬁltered,
sterile phosphate buffered saline (150 μL) were then
added prior to ﬂow cytometry (BD FACSCalibur,
CELLQuest software). A MP gate was deﬁned according
to side scatter using Megamix SSc beads (Biocytex,
France) following the International Society for Throm-
bosis and Haemostasis working group protocol [11] using
a validated ﬂow cytometer for MP analysis.
Soluble intercellular adhesion molecule-1 (ICAM-1)
analysis
Blood samples were collected by standard venepuncture
from an antecubital vein into serum collection tubes
(Greiner, UK). Samples were allowed to clot (30 min) then
centrifuged for 10 min at 2000 × g. Serum was carefully
removed and stored at −80 °C until analysis. Soluble
ICAM-1 was quantiﬁed within these samples using a
commercially available kit (BMS-241, Thermo-Fisher, UK)
following the manufacturers’ instructions.
Statistical analysis
Groups were merged for statistical analysis into PCOS, T2D
and non-diabetic controls. Analysis of variance (one-way
ANOVA) was used for comparison of CD105:CD106MP
ratios across groups and between males and females in the
mixed sex groups and BMI with signiﬁcance set at 0.05.
Post hoc Tukey's test was carried out to identify differences
between the groups. Pearson’s correlation was used to
investigate the relationship of the EMP ratio with age
and BMI.
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Results
Demographic data
The demographic data from the individual study groups are
shown in Table 1. Comparisons were made between age,
BMI and male/female recruits. Groups were merged for
subsequent analyses.
CD105MP:CD106MP ratio
The CD105MP:CD106MP ratio for the individual groups is
shown in Fig. 1a and merged group data in Fig. 1b.
Between groups analysis (PCOS, T2D and controls)
showed a highly signiﬁcant difference between the groups
(F= 63.43, p < 0.0001). Post-hoc analysis showed in
women with PCOS the CD105MP:CD106MP ratio was
signiﬁcantly different to both the T2D groups (p < 0.0001)
and the control groups (p < 0.0001). No difference was
found between T2D groups and control groups (p= 0.59).
Male/female ratio in T2D and control groups
No difference was observed in the ratio of CD105MP:
CD106MP between male and female subjects combined
from the T2D and control populations (F= 0.015, p= 0.9).
BMI
There was an overall signiﬁcant difference in BMI between
the groups (F= 32.64, p < 0.001). Combined data showed a
median (IQR) of 26.6 (24.7–30.2) in the T2D control group,
31.4 (28–34.6) in the T2D group and 36.1 (30.48–41.5) in
the PCOS group. Within groups there was a weak to
moderate correlation between CD105:CD106 ratio and BMI
in the control group (r= 0.40) and no correlation in either
the T2D group (r= 0.07) or the PCOS group (r= 0.03).
Age
T2D group 1/2 and control groups 1/2 were age matched
but signiﬁcantly older than PCOS groups (p < 0.001).
Within groups there was no correlation between age and
CD105:CD106MP ratio (r= 0.17 [controls], r= 0.13
[T2D] and r= 0.07 [PCOS]).
Soluble ICAM-1
Serum levels of ICAM-1 were quantiﬁed by ELISA on a
number of samples across PCOS (n= 37), T2D (n= 56)
and control groups (n= 18). PCOS was associated with
signiﬁcantly higher serum ICAM-1 (median 1318 ng/ml
[IQR 792–1581]) than either T2D (841 ng/ml [726–1010])
or control (746 ng/ml [668–823]) groups (F= 14.5, p <
0.001) as shown in Fig. 2. There was no signiﬁcant dif-
ference observed between T2D and control groups.
Markers of insulin resistance
Where data were available there was no correlation between
HOMA-IR and CD105:CD106MP within the PCOS group
(r= 0.004) nor was there any observed correlation between
HbA1c levels and CD105:CD106MP ratio within the T2D
group (r= 0.132) or the control group (r= 0.334). Also
within a PCOS group there was no correlation between
triglycerides and CD105:CD106MP ratio (r= 0.219).
Discussion
Endothelial MP may provide an insight into the state of the
endothelium in vivo. The use of MP ratios as presented here
offers a novel analysis method to compare data generated
across studies. The analysis of MP ratios herein could aid in
the distinction between disease and healthy states. Previous
studies have focussed on platelet MP in relation to PCOS
and found elevated levels [12–14]. Endothelial, platelet and
leucocyte-derived MP were also shown to be signiﬁcantly
higher in women with PCOS than controls, suggesting MP
could be a biomarker of PCOS [8]. In the present study this
concept is expanded upon to show that ratios of EMP can be
used to discriminate between conditions associated with
endothelial dysfunction, conﬁrming the notion of EMP as
biomarkers in PCOS. Based on the analysis presented, it is
suggested that utilising a particular EMP ratio, for example
CD105:CD106 would allow for comparisons to be made
across multiple sites and studies where it has been recently
shown that even when using a standardised technique and
reagents individual sample variability can be as high as 37%
[15]. Other markers which may be useful could include
other activation markers such as CD54 or CD62E. Serum
Table 1 Demographic data
Group PCOS 1 PCOS 2 PCOS 3 PCOS 4 T2D 1 T2D 2 T2D Control 1 T2D Control 2
Age 31.0 ± 5.8 26.5 ± 5.0 28.6 ± 5.5 29.1 ± 7.5 61.4 ± 10.8 62.0 ± 7.0 56.3 ± 9.8 55.0 ± 10
BMI 38.8 ± 7.8 37.2 ± 6.1 35.4 ± 10 33.8 ± 7.2 26.8 ± 5.4 32 ± 4 31.6 ± 5.8 28 ± 3
% Male 0 0 0 0 70.9 52.2 45.0 45.5
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levels of ICAM-1 were shown here to be signiﬁcantly
higher than either T2D or control groups and women with
PCOS have previously been shown to have increased serum
levels of inﬂammatory markers such as CD62E and
VCAM-1 in addition to ICAM-1 [16]. Furthermore, levels
of pro-inﬂammatory cytokines, especially interleukin-18,
which stimulates the synthesis of interleukin-6 are increased
[17].
The data presented here suggest a shift in EMP release in
women with PCOS towards a CD106 dominant proﬁle,
whereas all other groups showed a dominant CD105 proﬁle.
Women with PCOS had on average an approximate 2:1
ratio of CD106MP to CD105MP. This may be indicative of
endothelial cell activation or endothelial dysfunction over
and above anything observed within the diabetes groups or
a reﬂection of a differing EMP release mechanism in these
women. Obviously PCOS only occurs in females and so the
observed data could suggest a hormonal or medication
dependent change in EMP release however the T2D and
non-diabetic control groups analysed included females and
analysis showed no difference in CD105:CD106MP ratio
within the two diabetes with controls studies when
accounting for sex alone.
Though gender did not appear to inﬂuence EMP ratio,
age and BMI might be anticipated to be inﬂuencing factors
as endothelial function becomes poorer with age [18].
However, we found no signiﬁcant difference in CD105:
CD106 MP ratio between patients with T2D and healthy
a
b
Fig. 1 a The CD105:CD106 MP
ratio across individual studies.
Groups were PCOS 1 groups
1–4, T2D groups 1 and 2 and
control groups 1 and 2. Error
bars represent SEM. b Box plot
showing combined data for
PCOS, T2D and controls
groups. Horizontal bar within
the box represents the median,
‘x’ denotes mean
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age-matched controls, suggesting that the difference seen in
women here were due to the prevalence of PCOS in those
groups. Furthermore, there were no signiﬁcant within group
correlations between age or BMI and CD105:
CD106MP ratio.
The T2D CD105:CD106 MP ratio did not differ sig-
niﬁcantly from the control group despite T2D being asso-
ciated with impaired endothelial function. The T2D groups
were on medication for diabetes but the PCOS groups were
not on any form of insulin control medication. The observed
similarity in ratio of the T2D and control groups could
therefore be a consequence of medication and would be a
limitation of the study warranting further investigation.
Serum ICAM-1 was determined in a subset of patients and
showed that women with PCOS had a signiﬁcantly higher
serum ICAM-1 concentration thus conﬁrming altered
endothelial cell function or activation.
PCOS is associated with chronic low grade inﬂammation
that may contribute to an increased risk of future cardio-
vascular events, and may contribute to the underlying
pathology of the endocrine and metabolic abnormalities
including endothelial dysfunction that is found [19]. It has
also been demonstrated in several studies that PCOS is
directly correlated with endothelial dysfunction and vas-
cular anomalies and patients are at increased cardiovascular
risk [16, 20–22]. Paradisi et al. [23] reported that women
with PCOS had a signiﬁcant (ca. 50%) reduction in
endothelium-mediated vasodilation and in addition insulin
resistance and elevated testosterone levels were associated
with this reduction. Moreover, a study on PCOS women
that used cardiovascular magnetic resonance to measure
endothelial function of vessels established that endothelial
dysfunction was signiﬁcantly decreased (p < 0.01) with
ﬂow-mediated dilatation [24].
Endothelial dysfunction can also be evaluated by quan-
tifying speciﬁc indicators of coagulation such as plasmi-
nogen activator inhibitor-1 (PAI-1), markers of
inﬂammation (e.g. ICAM-1 and VCAM-1, or circulating
markers derived from the endothelium such as ADMA
(asymmetric dimethylarginine). The levels of such markers
of endothelial dysfunction (PAI-1, ADMA, VCAM-1, and
ICAM-1) have also shown to be higher in PCOS patients as
compared with controls [25]. In a meta-analysis PCOS
patients were reported to have a signiﬁcantly higher pre-
valence of endothelial dysfunction (as measured by low
ﬂow mediated dilatation) with subsequent higher risk of
future cardiovascular events as compared with their age and
weight matched controls, effects that were independent of
their age and normal BMI [26]. A recent study showed that
platelet-associated arginase activity was signiﬁcantly higher
in PCOS compared with a control group and that platelet
MP were increased in PCOS and were the main source of
circulating arginase activity [27]. This could impact vas-
cular homoeostasis and lead to cardiovascular disease via
arginase competition for L-arginine with endothelial nitric
oxide synthase [27, 28].
Conclusion
This report highlights the use of endothelial cell derived MP
ratios as a way to compare and contrast multiple studies of
endothelial function and demonstrates that women with
PCOS have an altered MP proﬁle with a CD106 dominant
phenotype.
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control groups (n= 18) as determined by ELISA. Horizontal bar
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